What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes
Not yet recruitingOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
January 1, 2026
Primary Completion Date
January 1, 2028
Study Completion Date
March 1, 2028
Conditions
Myelo Dysplastic Syndrome
All Listed Sponsors
lead
Assiut University
OTHER
NCT07210034 - What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter